
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is viewed favorably because its DRP platform may improve patient selection and increase the probability that stenoparib shows meaningful benefit in advanced ovarian cancer and recurrent SCLC, supporting a precision-medicine edge in a high-unmet-need setting. Clinical signals are encouraging, with multiple ovarian cancer patients exceeding 30 weeks on therapy, two still benefiting more than 29 months as of March 2026, and median overall survival now exceeding 25 months, while SCLC first dosing in February 2026 broadens the pipeline. Financially, the company had $20 million in cash and $22 million in debt in Q1, and exposure to a PARP inhibitor market that generated about $9.0 billion in 2023 and is forecast to surpass $21.0 billion by 2031 adds substantial commercial upside.
Bears say
Allarity Therapeutics is a clinical-stage company with essentially no revenue, reporting about $0 million in both Q1 2026 and Q2 2026, while posting net losses of $2.8 million and $3.4 million, respectively, underscoring its dependence on external funding rather than operating cash flow. Its lead stenoparib program still faces long development challenges, and the company’s value remains highly contingent on clinical success, regulatory approval, and eventual commercialization of a precision-medicine strategy that has yet to prove itself. The negative outlook is further supported by explicit balance sheet and liquidity risks, plus the possibility that safety, efficacy, reimbursement, competition, and broader biotech sentiment could all delay or impair progress.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Allarity Therapeutics (ALLR) Forecast
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares